Literature DB >> 19819953

The blood-brain barrier thyroxine transporter organic anion-transporting polypeptide 1c1 displays atypical transport kinetics.

Daniel E Westholm1, David R Salo, Kevin J Viken, Jon N Rumbley, Grant W Anderson.   

Abstract

Organic anion-transporting polypeptide (Oatp) 1c1 is a high-affinity T(4) transporter expressed in brain barrier cells. Oatp1c1 transports a variety of additional ligands including the conjugated sterol estradiol 17beta-glucuronide (E(2)17betaG). Intriguingly, published data suggest that E(2)17betaG inhibition of Oatp1c1-mediated T(4) transport exhibits characteristics suggestive of atypical transport kinetics. To determine whether Oatp1c1 exhibits atypical transport kinetics, we first performed detailed T(4) and E(2)17betaG uptake assays using Oatp1c1 stably transfected HEK293 cells and a wide range of T(4) and E(2)17betaG concentrations (100 pm to 300 nm and 27 nm to 200 mum, respectively). Eadie-Hofstee plots derived from these detailed T(4) and E(2)17betaG uptake experiments display a biphasic profile consistent with atypical transport kinetics. These data along with T(4) and E(2)17betaG cis-inhibition dose-response measurements revealed shared high- and low-affinity Oatp1c1 binding sites for T(4) and E(2)17betaG. T(4) and E(2)17betaG recognized these Oatp1c1 binding sites with opposite preferences. In addition, sterols glucuronidated in the 17 or 21 position, exhibited preferential substrate-dependent inhibition of Oatp1c1 transport, inhibiting Oatp1c1-mediated E(2)17betaG transport more strongly than T(4) transport. Together these data reveal that Oatp1c1-dependent substrate transport is a complex process involving substrate interaction with multiple binding sites and competition for binding with a variety of other substrates. A thorough understanding of atypical Oatp1c1 transport processes and substrate-dependent inhibition will allow better prediction of endo- and xenobiotic interactions with the Oatp transporter.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19819953     DOI: 10.1210/en.2009-0769

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  Targeting blood-brain barrier changes during inflammatory pain: an opportunity for optimizing CNS drug delivery.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Ther Deliv       Date:  2011-08

2.  An improved nonlinear model describing the hepatic pharmacokinetics of digoxin: evidence for two functionally different uptake systems and saturable binding.

Authors:  Michael Weiss; Peng Li; Michael S Roberts
Journal:  Pharm Res       Date:  2010-07-13       Impact factor: 4.200

Review 3.  Blood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in stroke.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Molecular characterization of zebrafish Oatp1d1 (Slco1d1), a novel organic anion-transporting polypeptide.

Authors:  Marta Popovic; Roko Zaja; Karl Fent; Tvrtko Smital
Journal:  J Biol Chem       Date:  2013-10-14       Impact factor: 5.157

5.  Functional Expression of Organic Anion Transporting Polypeptide 1a4 Is Regulated by Transforming Growth Factor-β/Activin Receptor-like Kinase 1 Signaling at the Blood-Brain Barrier.

Authors:  Wazir Abdullahi; Hrvoje Brzica; Nicholas A Hirsch; Bianca G Reilly; Patrick T Ronaldson
Journal:  Mol Pharmacol       Date:  2018-09-27       Impact factor: 4.436

6.  Lack of Influence of Substrate on Ligand Interaction with the Human Multidrug and Toxin Extruder, MATE1.

Authors:  Lucy J Martínez-Guerrero; Mark Morales; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2016-07-14       Impact factor: 4.436

7.  Inflammatory pain signals an increase in functional expression of organic anion transporting polypeptide 1a4 at the blood-brain barrier.

Authors:  Patrick T Ronaldson; Jessica D Finch; Kristin M Demarco; Colleen E Quigley; Thomas P Davis
Journal:  J Pharmacol Exp Ther       Date:  2010-12-02       Impact factor: 4.030

8.  Developmental and cell-specific expression of thyroid hormone transporters in the mouse cochlea.

Authors:  David S Sharlin; Theo J Visser; Douglas Forrest
Journal:  Endocrinology       Date:  2011-08-30       Impact factor: 4.736

9.  Substrate-dependent ligand inhibition of the human organic cation transporter OCT2.

Authors:  Mathew Belzer; Mark Morales; Bhumasamudram Jagadish; Eugene A Mash; Stephen H Wright
Journal:  J Pharmacol Exp Ther       Date:  2013-05-24       Impact factor: 4.030

Review 10.  Targeted drug delivery to treat pain and cerebral hypoxia.

Authors:  Patrick T Ronaldson; Thomas P Davis
Journal:  Pharmacol Rev       Date:  2013-01-23       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.